High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays.

Human stem cell derived cardiomyocytes (hESC-CM) provide a potential model for development of improved assays for pre-clinical predictive drug safety screening. We have used multi-electrode array (MEA) analysis of hESC-CM to generate multi-parameter data to profile drug impact on cardiomyocyte electrophysiology using a panel of 21 compounds active against key cardiac ion channels. Our study is the first to apply multi-parameter phenotypic profiling and clustering techniques commonly used for high-content imaging and microarray data to the analysis of electrophysiology data obtained by MEA analysis. Our data show good correlations with previous studies in stem cell derived cardiomyocytes and demonstrate improved specificity in compound risk assignment over convention single-parametric approaches. These analyses indicate great potential for multi-parameter MEA data acquired from hESC-CM to enable drug electrophysiological liabilities to be assessed in pre-clinical cardiotoxicity assays, facilitating informed decision making and liability management at the optimum point in drug development.

[1]  Tianen Yang,et al.  Alfuzosin Delays Cardiac Repolarization by a Novel Mechanism , 2008, Journal of Pharmacology and Experimental Therapeutics.

[2]  N. Thomas.  Review Article: High-Content Screening: A Decade of Evolution , 2010, Journal of biomolecular screening.

[3]  Yvonne Will,et al.  Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  J. Verducci,et al.  MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes , 2013, Scientific Reports.

[5]  Gary Gintant,et al.  An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. , 2011, Pharmacology & therapeutics.

[6]  Gary R. Mirams,et al.  Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk , 2011, Cardiovascular research.

[7]  Karl-Heinz Boven,et al.  Micro-Electrode Arrays in Cardiac Safety Pharmacology , 2004, Drug safety.

[8]  James W Kramer,et al.  Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. , 2013, Toxicology and applied pharmacology.

[9]  Amy Pointon,et al.  Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[10]  Hugo M. Vargas,et al.  Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay. , 2013, Journal of pharmacological and toxicological methods.

[11]  Norio Nakatsuji,et al.  Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development. , 2010, Current stem cell research & therapy.

[12]  Micha E. Spira,et al.  Toward on-chip, in-cell recordings from cultured cardiomyocytes by arrays of gold mushroom-shaped microelectrodes , 2012, Front. Neuroeng..

[13]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[14]  Clay W Scott,et al.  Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. , 2013, Toxicology letters.

[15]  A. Bruening-Wright,et al.  The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. , 2010, Journal of pharmacological and toxicological methods.

[16]  Kelly Rae Chi.  Revolution dawning in cardiotoxicity testing , 2013, Nature Reviews Drug Discovery.

[17]  Martin Traebert,et al.  Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation. , 2012, Heart rhythm.

[18]  Liang Guo,et al.  Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  E. Wegman.  Hyperdimensional Data Analysis Using Parallel Coordinates , 1990 .

[20]  Gary A Gintant,et al.  In Vitro Preclinical Cardiac Assessment of Tolterodine and Terodiline: Multiple Factors Predict the Clinical Experience , 2006, Journal of cardiovascular pharmacology.

[21]  Lior Gepstein,et al.  In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.

[22]  Robert Passier,et al.  Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.

[23]  Thomas Weiser,et al.  The Electrophysiological Effects of Cardiac Glycosides in Human iPSC-derived Cardiomyocytes and in Guinea Pig Isolated Hearts , 2011, Cellular Physiology and Biochemistry.

[24]  James A Thomson,et al.  High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.

[25]  M. Watzele,et al.  Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment , 2012, British journal of pharmacology.

[26]  Gary A Gintant,et al.  Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety , 2006, Toxicologic pathology.

[27]  Andreas Luch,et al.  Developmental toxicity testing in the 21st century: the sword of Damocles shattered by embryonic stem cell assays? , 2011, Archives of Toxicology.

[28]  Liang Guo,et al.  Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  J Vicente,et al.  Improving the Assessment of Heart Toxicity for All New Drugs Through Translational Regulatory Science , 2014, Clinical pharmacology and therapeutics.

[30]  Ulrich Egert,et al.  Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology Estimation of Action Potential Changes from Field Potential Recordings in Multicellular Mouse Cardiac Myocyte Cultures Key Words Microelectrode Array @bullet Action Potential Upstroke @bullet Action P , 2022 .

[31]  Tomoaki Inoue,et al.  Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. , 2011, Journal of pharmacological sciences.

[32]  N. McMahon,et al.  Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[33]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.